Basal insulin therapy is recommended as a first-line injectable therapy in persons with type 2 diabetes who do not respond to metformin monotherapy. Insulin works to control fasting glycaemia, and it is expected that metformin (with or without other drugs) will suffice apropos post-prandial euglycaemia. In many patients, however, basal insulin is unable to achieve adequate glycaemic control. This has been termed basal insulin failure. However, in the light of newer developments, we suggest a more appropriate term, basal insulin inadequacy, and discuss how it can be used.

Basal Insulin Failure {#s1}
=====================

According to the current American Diabetes Association (ADA)/ European Association for Study of Diabetes (EASD) guidelines, change of basal insulin therapy is indicated if the treatment strategy fails to achieve normal glycated haemoglobin (HbA~1c~) in spite of adequate fasting control, or if \>0.5 μ/kg/day of basal insulin is required.^[@R1]^ Basal insulin failure has earlier been defined as the inability to achieve a pre-decided target glycaemic control, after optimisation of lifestyle modification measures and maximal titration of basal dose beyond which unacceptable hypoglycaemia will occur.^[@R2]^

Basal Insulin Inadequacy {#s2}
========================

The current nomenclature implies that basal insulin has 'failed', while actually it may have succeeded in achieving fasting euglycaemia. Thus a more appropriate terminology is 'basal insulin inadequacy'. This conveys a more accurate message that basal insulin is inadequate for the particular patient's need. Inadequacy avoids the negative connotation associated with the word 'failure'. It does not pass judgmental opinion on either the patient's efforts to manage lifestyle or the physician's choice of therapeutic strategy.

Basal Insulin Dissimilarity {#s3}
===========================

All basal insulins are not alike. Each basal insulin and basal analogue has a unique structure, which contribute to specific pharmacokinetic and pharmacodynamic characteristics.^[@R3]^ These properties allow a systematic listing of basal insulin as intermediate-, long- and ultra-long-acting molecules (see *[Tables 1](#T1){ref-type="table"}* and *[2](#T2){ref-type="table"}*). The differences in duration of action, glycaemic variability and risk of hypoglycaemia, specifically nocturnal hypoglycaemia, may allow for substitution of one basal insulin for another, in case adequate control is not achieved with a particular preparation. Thus, a new strategy for intensification of therapy is available for persons not responding to basal therapy: a switch to a longer-acting basal insulin.

###### Classification of Basal Insulins and Insulin Regimes

  ------------------------ --------------------------------
  Intermediate acting      Neutral protamine Hagedorn
  Long acting              Glargine, detemir
  Ultra-long acting        Degludec
  Of historical interest   Lente, semi-lente, ultra-lente
  ------------------------ --------------------------------

Such a therapy is supported by mechanistic studies, randomised controlled trials (RCTs) and meta-analysis. Insulin degludec, for example, has been shown to have a longer half-life and duration of action, with significantly less glycaemic variability than glargine.^[@R4]^

RCTs and meta-analyses report a significantly lower incidence of hypoglycaemia and nocturnal hypoglycaemia, while achieving better fasting glucose control, in persons randomised to insulin degludec compared with glargine.^[@R5]--[@R8]^ Refractory patients, switched from glargine to degludec, have also been reported to achieve good glycaemic control in clinical practice.^[@R9],[@R10]^ Cost-effectiveness of such a shift is also found to be beneficial.^[@R11],[@R12]^ Thus, the clinical phenomenon of 'basal insulin inadequacy' may be drug-specific. Inability of a particular basal insulin to achieve adequate glycaemic control does not imply that all basal insulins will be inadequate for the purpose. Applied to a patient not responding to glargine, the phrase 'basal insulin inadequacy' may not be valid for all basal insulins.

###### Comparison of Basal Insulins and Insulin Analogues

  Insulin                                                             NPH                                                                                                          Glargine                                                                                                                        Detemir                                                                              Degludec
  ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------
  Structure                                                           Addition of protamine to unmodified human insulin, in quantity sufficient to complex all insulin molecules   Acidic long-acting analogue with substitution of asparagine with glycine at A21, and addition of two arginine residues at B30   Deletion of threonine at B30 and addition of aliphatic fatty acid to lysine at B29   Deletion of threonine at B30 and addition of 16-chain carbon fatty di-acid to lysine at B29 with glutamic acid as a spacer
  Number of amino acids                                               51                                                                                                           53                                                                                                                              50                                                                                   50
  Appearance                                                          Cloudy                                                                                                       Clear                                                                                                                           Clear                                                                                Clear
  Onset of action                                                     2--3 h                                                                                                       1--4 h                                                                                                                          1--4 h                                                                               --
  Half-life                                                           --                                                                                                           12.5 h                                                                                                                          12.5 h                                                                               25 h
  Duration of action                                                  Up to 18 h                                                                                                   Up to 24 h                                                                                                                      16-24 h                                                                              Up to 42 h
  Mechanism of protraction                                            Slow dissociation                                                                                            Precipitates form in subcutaneous tissue and dissociate slowly                                                                  Reversible binding with albumin and slow dissociation of multimers                   Multi-hexamers form in subcutaneous tissue and dissociate slowly
  Binding affinity to IGF-I receptor (human insulin 100)              100                                                                                                          641±51                                                                                                                          18±2                                                                                 2
  Binding affinity to insulin receptor (human insulin 100)            100                                                                                                          86±3                                                                                                                            16±1                                                                                 13-15
  Variability                                                         High                                                                                                         Medium                                                                                                                          Low                                                                                  Very low
  Ratio of exposure over first 12 h and second 12 h after injection   --                                                                                                           60:40                                                                                                                           50:50                                                                                50:50
  Risk of hypoglycaemia                                               May occur                                                                                                    Low                                                                                                                             Low                                                                                  Minimal
  Risk of nocturnal hypoglycaemia                                     May occur                                                                                                    May occur                                                                                                                       Minimal                                                                              Minimal
  Risk of weight gain                                                 Yes                                                                                                          Yes                                                                                                                             No                                                                                   Minimal
  Injection-site reactions                                            Rare                                                                                                         Possible, because of acidic pH                                                                                                  Rare                                                                                 Rare
  Miscibility with rapid-acting insulin                               Yes                                                                                                          No                                                                                                                              No                                                                                   Yes
  Miscibility with GLP1RA                                             No                                                                                                           Yes (with lixisenatide)                                                                                                         No                                                                                   Yes (with liraglutide)
  Frequency of administration                                         Once to twice daily                                                                                          Once daily                                                                                                                      Once to twice daily                                                                  Once daily
  Timing of administration                                            At same time every day                                                                                       At same time every day                                                                                                          At same time every day                                                               At any time of the day

GLP1RA = glucagon-like peptide-1 receptors agonists; IGF-1 = insulin-like growth factor 1; NPH = neutral protamine Hagedorn. Modified with permission from Kalra S, Newer basal insulin analogues: degludec, detemir, glargine, *J Pak Med Assoc*, 2013;63(11):1442-4.^[@R3]^

We therefore suggest the following terminology and definitions:

-   Basal insulin inadequacy may be defined as the inability of all basal insulin preparations, prescribed alone or in combination with various oral glucose-lowering drugs, to achieve pre-decided glycaemic targets, without causing unacceptable hypoglycaemia or weight gain, in spite of optimal lifestyle modification and maximal dose titration.

-   Intermediate-, long-acting and ultra-long-acting insulin inadequacy may be used to describe persons who do not respond to maximal doses of NPH, glargine and detemir and degludec, respectively.
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